For instance, constitutively activating mutations in Notch1 and Notch2 are equally oncogenic in a subset of triple negative breast cancer (TNBC) (141), despite the fact that Notch2 has been described as a tumor suppressor in TNBC cell lines (137). Here, NOTCH2 is linked to triple-negative breast carcinoma.